Prostaglandin (PG) E 2 inhibits hepatic stellate cell (HSC) mitogenesis. PGE-specific receptors are divided into four subtypes that are coupled either to Ca 2+ mobilization (EP1 and EP3) or to the stimulation of adenyl cyclase (EP2 and EP4). The aims of the current study were to identify PGE receptor subtypes in cultured rat HSC and to examine which PGE receptor subtype(s) mediates the inhibitory effect of PGE 2 on platelet-derived growth factor (PDGF)-stimulated proliferation. Reverse transcription-polymerase chain reaction analysis was performed to detect PGE receptor subtype mRNA expression. Cell proliferation was determined by measuring [ 3 H]thymidine incorporation, and intracellular cyclic AMP was measured by radioimmunoassay. Cultured rat HSC expressed mRNAs for all four subtypes of PGE receptor. PGE 2 -and EP2-selective agonist produced dose-dependent inhibitory effects on PDGF-stimulated proliferation. Neither EP1-, EP3-, nor EP4-selective agonists showed any inhibitory effect. An adenylate cyclase inhibitor strongly blunted the inhibition of DNA synthesis elicited by PGE 2 and the EP2 agonist. The EP2 agonist generated higher and more prolonged increases in intracellular cyclic AMP than the EP4 agonist. Activation of the PGE EP2 receptor has an antiproliferative effect in HSC that may be mediated by cyclic AMP-related signal transduction pathways.
classified as perisinusoidal cells involved in the storage and metabolism of vitamin A (2) . In disease conditions involving hepatic injury, HSC become activated, a process characterized by proliferation and transdifferentiation into myofibroblast-like cells and by the production of extracellular matrix components such as collagen and fibronectin (1, (3) (4) (5) (6) . The degree of fibrogenesis in liver diseases is most likely affected by the increased number of stellate cells, which results from their proliferation (7) . Development of pharmacological agents that inhibit HSC proliferation may lead to new treatment strategies for hepatic fibrosis.
In the liver, the five major prostanoids, prostaglandin (PG) D 2 , E 2 , F 2α , I 2 (prostacyclin), and thromboxane A 2 , are produced by nonparenchymal sinusoidal cells which comprise Kupffer cells, endothelial cells, and HSC (8) (9) (10) (11) . They are synthesized and released in response to various physiological and pathophysiological stimuli and control the function of sinusoidal cells in both an autocrine and a paracrine manner (12, 13) . In HSC, PGE 2 has been shown to inhibit cell proliferation induced by platelet-derived growth factor (PDGF), a key mitogen for HSC (14) (15) (16) (17) . The antiproliferative effect of PGE 2 has been suggested to be mediated by cyclic AMP-related signal transduction pathways (16, 17) . However, the mechanism responsible for this effect has not been fully clarified. PGE 2 exerts a wide range of biological actions through binding to specific receptors on plasma membranes (18, 19) . Recently, PGE receptors have been pharmacologically divided into four subtypes of the G protein-linked receptor family, called EP1, EP2, EP3, and EP4 (20, 21) , and these receptor subtypes have been identified at the molecular level (22) (23) (24) (25) (26) (27) (28) . They are coupled to Ca 2+ mobilization (EP1 and EP3) or to the stimulation of adenylate cyclase (EP2 and EP4) (20, 21) . Therefore, the aims of the current study were to identify PGE receptor subtypes and to examine which PGE receptor subtype(s) is involved in the inhibition of PDGF-stimulated proliferation by PGE 2 in cultured rat HSC.
MATERIALS AND METHODS
Test Reagents. PGE 2 and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma Chemical Co., St. Louis, MO. PGE receptor subtype-selective agonists, ONO-DI-004 (EP1-selective agonist), ONO-AE1-259-01 (EP2-selective agonist), ONO-AE-248 (EP3-selective agonist), and ONO-AE1-329 (EP4-selective agonist) were gifts from Ono Pharmaceutical Co., Ltd., Osaka, Japan. The specificity of the respective EP agonists was previously analyzed by measuring the binding affinity to the respective EP receptors expressed in CHO cells (29) . PDGF-BB was from Invitrogen Corp., Carlsbad, CA. The adenylate cyclase inhibitor SQ22536 was from Calbiochem-Novabiochem Co., La Jolla, CA.
Isolation and Culture of HSC. HSC were isolated from retired male breeder Sprague-Dawley rats (weight range, 500-700 g; Shizuoka Laboratory Animal Center, Shizuoka, Japan), that had consumed a standard pelleted diet and water ad libitum, as described previously (30) . Briefly, the livers were perfused sequentially with 0.3% pronase E (Boehringer Mannheim, Mannheim, Germany) in Dulbecco's modified Eagle's medium and Ham's nutrient mixture F-12 (DME; Sigma) followed by 0.015% collagenase B (Boehringer Mannheim) in DME. After the digested livers were dispersed into DME containing 10 mg/mL deoxyribonuclease 1 (Sigma), the resultant cell suspension was centrifuged on a single-step Nycodenz (Nycomed Pharma AS, Oslo, Norway) gradient (final concentration, 9.2%). After centrifugation, HSC were obtained from the upper, whitish layer and resuspended in M-199 (Sigma) containing 10% fetal bovine serum (FCS; Gibco BRL, Grand Island, NY) and 10% horse serum (Gibco BRL) (termed complete medium). The cells were plated on uncoated plastic at a density of 1.5 × 10 5 cells/well in 48-well plates. After plating, the medium was changed every 24 hr. The purity of HSC at isolation was 75-85% as assessed by the characteristic of rapidly fading bluegreen autofluorescence when exposed to light at a wavelength of 328 nm. The viability was more than 95% as assessed by trypan blue exclusion. After 3 days in culture in complete medium, the purity and viability were >99 and >95%, respectively. All animals received humane care in accordance with the guidelines of the Animal Care Committee of Hamamatsu University School of Medicine.
Polymerase Chain Reaction (PCR) Detection of PGE Receptor Subtype mRNAs. Cells cultured for 3 days in complete medium were harvested after trypsinization. Total RNA was isolated using TRIzol reagent (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's instructions. Reverse transcription with oligo(dT) priming was used to generate cDNAs from total RNA (2-µg) extracts. The synthesized cDNAs for EP1, EP2, EP3, EP4, and β-actin were amplified using specific sets of primers. The sequences of some primers were previously described (EP2 (31) and β-actin [32] ), and others were designed based on published cDNA sequences (EP1 [33] , EP3 [34] , and EP4 [35, 36] • C for 1 min, annealing at 58
• C for 1 min, and extension at 72
• C for 2 min, with initial denaturation of sample cDNA at 95
• C for 2 min and an additional extension period of 4 min after the last cycle. The PCR products were subjected to 1.5% agarose gel electrophoresis and visualized by staining with ethidium bromide. For positive PCR controls, plasmid DNAs encoding the rat prostanoid EP1, EP2, EP3, and EP4 receptor subtypes (kindly provided by S. Narumiya) were used.
Cell Proliferation Studies. Cell proliferation was determined by [ 3 H]thymidine incorporation into DNA as described previously (30) . After 3 days in culture in complete medium, under subconfluent conditions, HSC were treated with 0.4% FCS medium containing PGE 2 , PGE receptor subtype-selective agonists, or vehicle (0.1% dimethylsulfoxide [DMSO]) for 1 hr, followed by 0.4% FCS medium containing 10 ng/mL PDGF plus the test compounds or vehicle for an additional 24 hr, and were labeled with 2 µCi/ml [methyl-
3 H]thymidine (6.7 Ci/mmol; New England Nuclear, Boston, MA) for the last 16 hr of incubation. In some experiments, the cells were exposed to the adenylate cyclase inhibitor SQ22536 (1 mM) or vehicle 30 min before treatment with the test compounds. After the cells were washed twice with cold phosphate-buffered saline (PBS), they were immersed in 10% trichloroacetic acid on ice for 10 min, washed twice with 80% ethanol, and solubilized in 1 N NaOH, 0.1% SDS at 37
• C for 1 hr. After neutralization with 1 N HCl, [ 3 H]thymidineincorporated radioactivity was determined in the cell extracts by liquid scintillation counting.
Determination of Intracellular Cyclic AMP Levels. For measurement of cyclic AMP cell content, the cell medium was changed to one containing 0.4% FCS for 1 hr, and then the HSC were incubated with 0.4% FCS medium containing the test reagents for different times in the presence of IBMX (0.5 mM) for the last 30 min of incubation. The medium was aspirated at the end of incubation, and the cells were treated with 10 mM acetic acid for 1 hr at 4
• C to extract intracellular cyclic AMP. The extract was lyophilized before acetylation of cyclic AMP by the method of Steiner (37). An 125 I-cyclic AMP radioimmunoassay (RIA) was performed using rabbit antiserum against cyclic AMP. The antiserum does not cross-react with guanosine 3 , 5 -cyclic monophosphate (cyclic GMP), and the minimum detection limit of the cyclic AMP assay was 4 fmol/ tube. The results are expressed as fentomoles of cyclic AMP per well.
Statistical Analysis. All data are expressed as the mean ± SE of four independent experiments performed in triplicate. The statistical significance of differences between groups was determined using ANOVA, with P < 0.05 considered significant.
RESULTS
Expression of PGE Receptor Subtypes. In order to investigate the expression of the four subtypes of PGE receptor, we performed reverse transcriptase (RT)-PCR in cultured rat HSC. As shown in Figure 1 , HSC expressed mRNAs for all four PGE receptor subtypes, EP1, EP2, EP3, and EP4. The molecular size of each RT-PCR product matched that of the control PCR product from plasmid DNA encoding the corresponding rat PGE receptor subtype.
Effects of PGE 2 and PGE Receptor SubtypeSelective Agonists on PDGF-Stimulated Cell Proliferation. As shown in Figure 2A , PGE 2 produced a dose-dependent inhibitory effect on PDGF-stimulated cell proliferation, with a maximum inhibition of 51% at a concentration of 1000 nM. ONO-AE1-259-01 (EP2 agonist; 0.1-100 nM) induced a dose-dependent inhibitory effect on PDGF-stimulated cell proliferation with a maximum inhibition of 51% at a concentration of 100 nM, while neither ONO-DI-004 (EP1 agonist; 10 or 1000 nM), ONO-AE-248 (EP3 agonist; 0.1-100 nM), nor ONO-AE1-329 (EP4 agonist; 0.1-100 nM) had a suppressive effect ( Figures 2B, C, D and E) .
To eliminate the possibility that ONO-AE1-259-01, an EP2-selective agonist, might be toxic for cultured rat HSC, cellular morphology, and cell viability were routinely assessed by phase-contrast microscopy and by trypan blue exclusion, respectively. No change in cellular morphology or cell viability was found in cells exposed to this compound compared with controls (data not shown).
As shown in Figure 2F , pretreatment with the adenylate cyclase inhibitor SQ22536 (1 mM) blunted the inhibition of HSC proliferation elicited by PGE 2 (1000 nM) and ONO-AE1-259-01 (10 nM).
Effects of PGE 2 and EP2 and EP4 ReceptorSelective Agonists on Intracellular Cyclic AMP Levels. As shown in Figure 3A , PGE 2 (1000 nM), ONO-AE1-259-01 (EP2 agonist; 100 nM), and ONO-AE1-329 (EP4 agonist; 100 nM) increased intracellular cyclic AMP by 2.5-, 2.1-, and 1.6-fold over basal, respectively, in the presence of IBMX, while neither ONO-DI-004 (EP1 agonist; 1000 nM) nor ONO-AE-248 (EP3 agonist; 100 nM) raised intracellular cyclic AMP. In addition, ONO-AE1-259-01 and ONO-AE1-329 dose dependently increased intracellular cyclic AMP ( Figure 3B ). As shown in Figure 3C , when the accumulation of intracellular cyclic AMP was evaluated at different times after treatment with ONO-AE1-259-01 (100 nM) or ONO-AE1-329 (100 nM), the EP2 agonist generated higher levels of cyclic AMP than the EP4 agonist at each time point, and the elevation of cyclic AMP levels above control was more prolonged for the EP2 agonist.
DISCUSSION
Under conditions of chronic liver injury, HSC become activated and demonstrate a proliferative, fibrogenic phenotype that can result in hepatic fibrosis (1) (2) (3) (4) (5) (6) (7) . HSC proliferation is a critical process in hepatic fibrogenesis because it increases in the population of activated, fibrogenic HSC. Agents that interfere with HSC proliferation might be of therapeutic value in the prevention and slowing of hepatic fibrogenesis. In the present study, PGE 2 was shown to attenuate PDGF-stimulated cell proliferation in cultured rat HSC, confirming the previous observations (14) (15) (16) (17) . In other cell types, a similar antiproliferative effect of PGE 2 has been reported (38, 39) . PGE 2 or its analogs may be potential candidates for the treatment of hepatic fibrosis as proposed previously (14, 40) .
PGE produces a broad range of biological effects in various tissues and cell types through its binding to specific receptors on the plasma membrane (18, 19) . The PGE receptor family comprises four receptor subtypes: EP1, EP2, EP3, and EP4 (20, 21) . In the present study, RT-PCR analysis showed that all four subtypes of PGE receptor were expressed in cultured rat HSC, similar to the findings of Fennekohl et al. (41) . PGE receptor subtypes are differentially expressed in various tissues and cell types, and each receptor subtype has particular physiological and pathophysiological roles (42) . However, the roles of the individual subtypes of PGE receptors in HSC have not been investigated previously.
To clarify which subtype(s) of PGE receptor is(are) involved in the PGE 2 -induced antiproliferative response, we examined the effects of PGE receptor subtype-selective agonists on PDGF-stimulated proliferation of cultured rat HSC. In the present study, ONO-AE1-259-01, an EP2 receptor-selective agonist, exclusively inhibited PDGFstimulated cell proliferation among the various PGE receptor subtype-selective agonists tested. This result suggests that PGE 2 may induce its antiproliferative response through binding to the PGE receptor subtype EP2.
When stimulated, EP2 and EP4 receptors activate adenylate cyclase, which generates intracellular cyclic AMP (29) . In the present study, PGE 2 , ONO-AE1-259-01, an EP2 receptor-selective agonist, and ONO-AE1-329, an EP4 receptor-selective agonist, were shown to cause an increase in intracellular cyclic AMP in cultured rat HSC. Recently, increased intracellular cyclic AMP has been demonstrated to inhibit HSC proliferation (16, 17, 30, 43, 44) . Therefore, the EP2 receptorselective agonist and PGE 2 may induce an antiproliferative effect via an elevation of intracellular cyclic AMP. This is strongly supported by our results showing that an adenylate cyclase inhibitor substantially blunted the inhibition of DNA synthesis elicited by both PGE 2 and the EP2 receptor-selective agonist. Unexpectedly, the EP4 receptor-selective agonist did not inhibit HSC proliferation. This may be due to functional heterogeneity of the two receptor subtypes. The EP4 receptor, but not the EP2 receptor, has been demonstrated to undergo agonistinduced desensitization several minutes after the addition of agonists (45) . In the present study, the EP2 receptorselective agonist was shown to generate higher intracellular cyclic AMP levels more than the EP4 receptor-selective agonist, and the EP4 agonist-induced cyclic AMP response returned to baseline more quickly than that of the EP2 receptor-selective agonist. Recently, the antimitogenic action of cyclic AMP has been proposed to require the elevation of intracellular cyclic AMP in the G1 phase of the cell cycle, which cells enter several hours after the addition of growth factors (46) . Therefore, the transient increase in cyclic AMP level induced by stimulation of the EP4 receptor may be insufficient to inhibit HSC mitogenesis.
In conclusion, this study demonstrated that cultured rat HSC express mRNAs for all four PGE receptor subtypes (EP1, EP2, EP3, and EP4) and that both PGE 2 and ONO-AE1-259-01, an EP2 receptor-selective agonist, inhibit PDGF-stimulated proliferation and increase intracellular cyclic AMP levels in cultured rat HSC. These results suggest that PGE 2 binding to the EP2 receptor causes an antiproliferative effect mediated by cyclic AMP-related signal transduction pathways in HSC. Activation of PGE EP2 receptors using compounds like ONO-AE1-259-01 may have the potential to inhibit hepatic fibrogenesis by decreasing HSC proliferation.
